Tsai Cheng-Hsuan, Salle Stefanie Parisien-La, Brown Jenifer M, Newman Andrew, Chang Chin-Chen, Wu Vin-Cent, Lin Yen-Hung, Vaidya Anand
Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 100, Taiwan.
Eur J Endocrinol. 2025 Aug 29;193(3):348-358. doi: 10.1093/ejendo/lvaf170.
The saline suppression test (SST) and the captopril challenge test (CCT) have traditionally been used to confirm or exclude primary aldosteronism (PA). New guidelines recommend using these tests to predict the likelihood of unilateral PA. This study evaluated the diagnostic accuracy, consistency, and clinical implications of these tests.
We conducted a retrospective study of 531 patients with high-probability features of PA who underwent both SST and CCT to evaluate their accuracy and ability to predict unilateral PA. Adrenal lateralization and surgical treatment decisions were guided by individualized clinical judgment rather than strictly relying on SST/CCT results.
The rate of PA diagnosis ranged from 47.8% to 97.2% based on SST and CCT criteria. Discordance rates between SST and CCT ranged from 10.9% to 51.6%. In analyses restricted to only patients with clinically overt PA, where suppression testing is not considered necessary, the positivity rates of the SST and CCT were still suboptimal and test discordance persisted. Among patients with lateralizing PA, 6.6% to 27.9% had either a negative SST or CCT interpretation, and among those who achieved Primary Aldosteronism Surgical Outcome-defined biochemical cure after unilateral adrenalectomy, 4.1% to 39.8% had either a negative SST or CCT, and up to 5.1% had false-negative results on both tests.
Well-established aldosterone suppression tests for PA demonstrated substantial inconsistency, false-negative interpretations, and the inability to reliably predict lateralization outcomes in PA. Aldosterone suppression testing, using SST and CCT, lack accuracy for the diagnosis and subtyping of PA in high-risk patients.
传统上,盐水抑制试验(SST)和卡托普利激发试验(CCT)用于确诊或排除原发性醛固酮增多症(PA)。新指南建议使用这些试验来预测单侧PA的可能性。本研究评估了这些试验的诊断准确性、一致性及临床意义。
我们对531例具有PA高概率特征的患者进行了一项回顾性研究,这些患者同时接受了SST和CCT,以评估其准确性及预测单侧PA的能力。肾上腺定位及手术治疗决策以个体化临床判断为指导,而非严格依赖SST/CCT结果。
根据SST和CCT标准,PA诊断率在47.8%至97.2%之间。SST和CCT之间的不一致率在10.9%至51.6%之间。在仅分析临床显性PA患者(不认为有必要进行抑制试验)时,SST和CCT的阳性率仍然不理想,试验不一致情况仍然存在。在单侧PA患者中,6.6%至27.9%的患者SST或CCT结果为阴性,在单侧肾上腺切除术后达到原发性醛固酮增多症手术结局定义的生化治愈的患者中,4.1%至39.8%的患者SST或CCT结果为阴性,高达5.1%的患者两项试验结果均为假阴性。
用于PA的成熟醛固酮抑制试验显示出显著的不一致性、假阴性结果,且无法可靠预测PA的定位结果。使用SST和CCT的醛固酮抑制试验在高危患者中对PA的诊断和分型缺乏准确性。